What “FDA exclusivity date” applies to Camptosar (camptothecin/camptosar)?
The FDA “exclusivity date” usually refers to when a drug’s regulatory exclusivities (most commonly for a reference-listed drug or brand product) expire, allowing generic manufacturers to potentially file later and/or launch sooner, depending on whether patents are also blocking competition. However, the key information needed to state an exact date for Camptosar is not provided here.
What I need to give you the exact exclusivity expiration date
To pinpoint the correct exclusivity, I need one of the following:
- the drug’s exact FDA product identifier (NDA/BLA number), or
- the “reference listed drug” (RLD) name and strength/labeling that matches the FDA exclusivity you care about, or
- permission to look up the FDA Orange Book listing for the specific Camptosar product you mean.
Camptosar also has multiple possible naming/labeling conventions over time, and exclusivity can differ by application and by whether you mean:
- exclusivity for the original brand approval versus
- exclusivity tied to specific supplemental approvals.
Does patent expiration control the real-world generic entry date too?
Even after exclusivity expires, generics typically cannot launch until relevant patents listed in the FDA Orange Book expire or are cleared. So the practical “when will generics launch” date is often later than the FDA exclusivity expiration date if patents are still in force.
Next step
Reply with either:
1) the NDA number for Camptosar you mean, or
2) the exact strength(s) and dosage form (from the FDA label you’re looking at),
and I’ll tell you the specific FDA exclusivity expiration date that matches that product and context.